

Synthesis of a Tetracyclic 2'-Deoxyadenosine Analog

Chris A. Buhr*, Mark D. Matteucci, and Brian C. Froehler

Gilead Sciences Inc.
333 Lakeside Drive, Foster City, CA 94404

Received 7 May 1999; accepted 28 September 1999

Abstract

A tetracyclic 2'-deoxyadenosine has been synthesized via a Stille biaryl coupling on a protected 6-chloro-7-deaza-7-iodopurine-2'-deoxyribose followed by cyclization. The nucleoside was incorporated into an oligodeoxynucleotide (ODN) and shown to pair with thymine. © 1999 Elsevier Science Ltd. All rights reserved.

Keywords: tetracyclic 2'-deoxyadenosine, 7-deaza-2'-deoxyadenosine

Replacement of a single 2'-deoxycytidine in an oligodeoxynucleotide (ODN) with either of the tricyclic 2'-deoxycytidine analogs **1** or **2** (Figure 1) has been shown to increase the affinity of the ODN towards its complementary RNA.¹ The tetracyclic adenosine analog **3** could be expected to enhance hybridization in an analogous fashion upon incorporation into an ODN. We report the synthesis of the novel adenosine analog **3**, as well as the protected hydrogen phosphonate **7**.





Figure 1.

The synthesis of **3** begins with 6-chloro-7-deaza-7-iodopurine-2'-deoxyribose **4**,^{2,3} and is depicted in Scheme 1. Stille coupling⁴ of the iodonucleoside **4**² and N-(tert-butoxycarbonyl)-2-(trimethylstannyl)aniline⁵ with bis(triphenylphosphine)palladium(II) chloride afforded biaryl nucleoside **5**. Treatment of **5** with 1,4-diazabicyclo[2.2.2]octane (Dabco)⁶ and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) formed the tetracyclic skeleton, presumably via activation of the chloro group of **5** followed by cyclization. Some of the Boc protecting group was removed during this step. Therefore the mixture of products was treated with trifluoroacetic acid (TFA) affording **6** in 96% yield from **5**. Removal of the toluoyl groups with NaOMe afforded the parent nucleoside **3**.⁷ Standard dimethoxy-tritylation and phosphitylation⁸ of **3** afforded the hydrogen phosphonate **7**.⁹

Incorporation of the tricyclic phenoxazine **1** has been shown to enhance cellular permeation of the oligonucleotides.¹⁰ Similarly, incorporation of the lipophilic tetracyclic **3** in combination with other lipophilic enhancements may render such ODN's permeable to cellular membranes. Thus, these ODN's may be useful as antisense reagents for in vitro and in vivo applications.¹¹

Scheme 1. Synthesis of Tetracyclic Nucleoside



Reaction conditions: (a) N-(tert-butoxycarbonyl)-2-(trimethylstannyl)aniline (4 eq.), (Ph₃P)₂PdCl₂ (0.1 eq.), DMF, 60 °C, 24 h; (b) Dabco (2 eq.), DBU (2 eq.), DMF, 75 °C, 21 h; (c) 25% TFA in CH₂Cl₂, 3 h, RT; (d) NaOMe, MeOH, RT; (e) DMT-Cl, pyridine; (f) 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one (10 eq.), pyridine, CH₂Cl₂, 0 °C to RT, 30 min.; (g) aq. triethylammonium bicarbonate.

References and Notes:

- a. Lin, K.-Y.; Jones, R.J.; Matteucci, M.D. *J. Am. Chem. Soc.* **1995**, *117*, 3873-3874; b. Matteucci, M.D., von Krosigk, U. *Tetrahedron Lett.* **1996**, *37*, 5057-5060; c. Kurchavov, N.A.; Stetsenko, D.A.; Skaptsova, N.V.; Potapov, V.K.; Sverdlov, E.D. *Nucleosides & Nucleotides* **1997**, *16*, 1837-1846.
- Buhr, C.A.; Wagner, R.W.; Grant, D.; Froehler, B.C. *Nucleic Acids Res.* **1996**, *24*, 2974-2980.
- For oligonucleotides containing other 7-deazapurine-2'-deoxyribose nucleosides see: a. Seela, F.; Ramzaeva, N.; Zulaf, M. *Nucleosides and Nucleotides* **1997**, *16*, 963-966; b. Ramzaeva, N.; Mittelbach, C.; Seela, F. *Helv. Chim. Acta* **1997**, *80*, 1809-1822; c. Seela, F.; Chen, Y. *Helv. Chim. Acta* **1997**, *80*, 1073-1086; and references cited within.
- Stille, J.K. *Angew. Chem. Int. Ed. Engl.* **1986**, *25*, 508-524.
- Gomez-Bengoa, E.; Echavarren, A.M. *J. Org. Chem.* **1991**, *56*, 3497-3501.
- A 1.5 M solution of Dabco in DMF was stored over activated 3Å molecular sieves. Aliquots of this solution containing the appropriate amounts of Dabco were added to the reaction.
- Compound 3: ¹H NMR (300 MHz, dms_o-d₆) δ 10.69 (1H, s, NH), 8.13 (1H, s, H₂), 7.62 (1H, d, J = 7.4 Hz, aryl CH), 7.48 (1H, s, H₈), 7.25-7.15 (2H, m, aryl CH), 7.15-7.00 (1H, m, aryl CH), 6.40 (1H, t, J = 6.8 Hz, 1'-H), 5.33 (1H, d, J = 3.6 Hz, 3'-OH), 5.22 (1H, t, J = 5.5 Hz, 5'-OH), 4.43 (1H, s, 3'-H), 3.90 (1H, s, 4'-H), 3.72-3.51 (2H, m, 5'-CH₂), 2.76-2.63 (1H, m, 2'-H_a), 2.34-2.22 (1H, s, 2'-H_b). The UV properties of compound 3 in MeOH are: ε₂₆₀ = 15,550 M⁻¹ cm⁻¹; λ_{max} = 228 nm, ε₂₂₈ = 23,540 M⁻¹ cm⁻¹. FAB MS: m/z calculated for C₁₇H₁₇N₄O₃ (MH⁺) 325.1300, found 325.1295.
- Froehler, B.C. in *Protocols for Oligonucleotides and Analogs: Synthesis and Properties*. Humana Totowa, Agrawal, S. ed., NJ, **1993**, pp 63-80.
- A single incorporation of 7 into a propyne containing phosphorothioate ODN was performed using the H-phosphonate method followed by S₈ oxidation.⁸ All ODN's, except complementary ODN's, were 2'-deoxyphosphorothioates. Complementary and mismatch complementary ODN's were diesters. Thermal melting measurements showed that the tetracyclic adenosine 3 paired with thymidine. One incorporation of tetracyclic adenosine 3 did not significantly change the T_m relative to a control in this context. Incorporation of multiple adjacent tetracyclic adenosine 3 may have a positive cumulative effect. Similar observations have been made in the tricyclic cytidine series.^{1a,c}
- Flanagan, W.M.; Wagner, R.W.; Grant, D.; Lin, K.-Y.; Matteucci, M.D. *Nature Biotechnology* **1999**, *17*, 48-52.
- a. Wagner, R.W., Flanagan, W.M. in *Applied Antisense Technology*. Wiley-Liss, Inc., Stein, C.A. Krieg, A.M. ed., NY, **1998**, 175-191; b. Agrawal, S., Zhao, Q. *Curr. Opin. Chem. Biol.* **1998**, *2*, 519-28; c. Crooke, S.T. *Biotechnol. Genet. Eng. Rev.* **1998**, *15*, 121-157; d. Matteucci, M.D., Wagner, R.W. *Nature* **1996**, *384*, 20-22.